Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $40.00, for a total value of $320,000.00. Following the transaction, the director now owns 12,000 shares of the company’s stock, valued at approximately $480,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Protagonist Therapeutics Price Performance
NASDAQ PTGX traded down $1.29 on Friday, hitting $40.28. The stock had a trading volume of 770,101 shares, compared to its average volume of 797,622. The business’s fifty day moving average price is $33.45 and its 200 day moving average price is $29.50. Protagonist Therapeutics, Inc. has a 52-week low of $13.72 and a 52-week high of $42.67. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of 17.04 and a beta of 2.13.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported $3.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.75. The firm had revenue of $254.95 million during the quarter, compared to analysts’ expectations of $300.00 million. As a group, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.28 EPS for the current year.
Analysts Set New Price Targets
Check Out Our Latest Report on Protagonist Therapeutics
Hedge Funds Weigh In On Protagonist Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in shares of Protagonist Therapeutics during the first quarter valued at $35,000. Lazard Asset Management LLC purchased a new stake in shares of Protagonist Therapeutics during the first quarter valued at $69,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Protagonist Therapeutics by 353.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,675 shares of the company’s stock valued at $153,000 after buying an additional 5,202 shares during the last quarter. Seven Eight Capital LP purchased a new stake in shares of Protagonist Therapeutics during the first quarter valued at $202,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Protagonist Therapeutics during the fourth quarter valued at $210,000. 98.63% of the stock is owned by hedge funds and other institutional investors.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Recommended Stories
- Five stocks we like better than Protagonist Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Health Care Stocks Explained: Why You Might Want to Invest
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.